JAZZ News and Press, Jazz Pharmaceuticals plc From 08/16/23

2023-08-16 03:00:21 ET Summary Baupost Group's 13F portfolio value decreased from $5.85B to $5.61B this quarter. The portfolio is heavily concentrated, with Liberty Global, Liberty Media Sirius XM, ViaSat, Alphabet, and Veritiv accounting for approximately 58% of the holdings. ...

2023-08-09 21:53:04 ET Jazz Pharmaceuticals plc (JAZZ) Q2 2023 Results Conference Call August 09, 2023 04:30 PM ET Company Participants Andrea Flynn - VP & Head, IR Bruce Cozadd - Chairman and Chief Executive Officer Renee Gala - Executive Vice President and ...

2023-08-09 16:09:03 ET Jazz Pharmaceuticals press release ( NASDAQ: JAZZ ): Q2 Non-GAAP EPS of $4.51 beats by $0.08 . Revenue of $957.32M (+2.6% Y/Y) beats by $15.16M . Raised full year 2023 financial guidance: Raised total and Neuroscience revenue guidance...

Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance PR Newswire – Strong execution delivered second quarter 2023 total revenues of $957 million – – Commercial excellence drove continued adop...

Jazz Pharmaceuticals enters into Letter of Intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for Rylaze®, helping address the unmet need of acute lymphoblastic leukemia and lymphoblastic lymphoma patients across Canada Canada NewsWire MISSISSAUGA, ON , ...

Jazz Pharmaceuticals to Report 2023 Second Quarter Financial Results on August 9, 2023 PR Newswire DUBLIN , July 26, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 second quarter financial results on We...

2023-07-25 04:47:39 ET Summary Jazz Pharmaceuticals' current valuation is significantly lower than the sector average, despite strong margins and a positive growth outlook, presenting a potential investment opportunity. The company is making progress in its clinical trials and is ...

2023-07-21 14:01:24 ET Summary Jazz Pharmaceuticals' share price has languished in FY'22 with a number of pressures on its Xywav label. The FDA has supported the competing Lumryz label, stating it is clinically superior to Xywav, chiefly due to its once-nightly dosing regimen. ...

Jazz Pharmaceuticals Receives CHMP Positive Opinion for JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma PR Newswire DUBLIN , July 21, 2023 /PRNewswire/ -- Jazz Pharmaceutica...

2023-07-20 15:26:42 ET Summary Avadel Pharmaceuticals plc finally won approval of Lumryz™ (sodium oxybate), despite cutthroat opposition from Jazz Pharmaceuticals plc. Potential sales estimate is $3bn. Avadel Pharmaceuticals is flying high, as it well should, but I am a...